Navigation Links
Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
Date:8/26/2010

CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Sermo (http://www.sermo.com/client), the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS).  According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care, Plavix (clopidogrel), for ACS patients. If approved, 57% of physicians said they could switch up to 20% of their patients to ticagrelor.

The Sermo Report polled 60 physicians, many of who also participated in a discussion about the treatment. Acute coronary syndrome (ACS) incorporates a number of symptoms consistent with the probability that a patient is suffering from active Myocardial Infarction. Competitors to ticagrelor include Bristol-Myers Squibb Co. and Sanofi-Aventis', Plavix and Effient, sold by Eli Lilly & Company.

"Physicians on Sermo see ticagrelor as significantly impactful to clinicians," said Adam Sharp, Chief Medical Officer at Sermo. "However, cost and time in market could slow adoption. While more research on physician awareness still needs to be done, it's also interesting to note that 50% of docs did not know about the FDA approval before seeing it on Sermo."

Highlights from the report include:

  • Cost, time in market and generic Plavix were identified as three issues that could dissuade physicians from writing ticagrelor.
  • Reversibility and less post-operative bleeding were identified as possible advantages of this medication over Plavix.

Physicians shared their views of ticagrelor:

"While cost is certainly an issue we deal with all the time (can't wait until Plavix goes generic), there are some advantages with this medication – the biggest being the reversibility. I would be curious to see in the future how cardiac surgeons feel when this drug is in use – will they find that the drug really is reversible and that they find less post-operative bleeding. This would be a clear benefit over Plavix."

--Cardiologist, Sermo physician

"I would wait for a year or two to start prescribing it systematically. This time should be sufficient to elucidate the side-effect profile of the drug."

---Critical Care, Sermo physician

The full Sermo report includes key findings, MD demographics and post analysis.

Download the free report at http://www.sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about drugs, devices, treatments, and trends. Data for Sermo Reports are gathered through Sermo Posts, which allow physicians to participate in a poll and discussion about the topic.

About Sermo

Sermo is the largest online physician community, where over 115,000 practicing physicians discuss clinical cases and get advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit http://www.sermo.com/clients.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
2. NCPA: AARP Report Finds Brand Name Drug Prices Soar as Large Pharmacy Benefit Managers Reap Windfall Profits
3. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
4. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Kewaunee Scientific Reports Sales and Earnings for First Quarter
7. Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market
8. Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
Breaking Medicine News(10 mins):